SPORE IN BREAST CANCER

我们在这里提出了一个卓越的研究乳腺癌的专业计划 癌症，以满足肿瘤社区的需要， 临床和实验室工作致力于降低 和乳腺癌的死亡率。孢子将由一个 主任一名科学协调员，一个指导委员会，五个主要 研究项目，两个核心资源（行政和病理学）， 发展研究计划和职业发展计划。 这些项目将包括对erbB-2、erbB-3和erbB-4的研究， 调蛋白、EGFR、ras和法尼基蛋白转移酶抑制剂、TC- 21，转化生长因子-β，代表性差异分析，易感性 BRCA 1、细胞周期蛋白和p53基因。这些实验室研究将 转化为对病因、诊断、分期的更好理解， 预后、治疗反应和生活质量。转向 委员会将由主任（诺顿博士），科学 协调员（N.罗森），乳腺病理学核心的负责人 资源（博士P. P.罗森），五个主要项目的领导人 (Drs. Aaronson，Massague，Mendelsohn，N.罗森、维格勒）、卢西奥博士 Luzzatto（人类遗传学）、Begg博士（生物统计学）、Lloyd Old博士 Borgen博士（外科），Beryl McCormick博士（放射科 和Amy Langer女士（全国联盟执行主任 乳腺癌组织）。加快改进的SPORE 网络，我们主张并将经常组织 受资助的SPORE的董事。我们还建议协调 我们与各NCI代表的活动- 申办的组织资源库/登记处（SPORE除外），以及 与乳腺癌合作小组委员会主席一起。我们 我设计了一个广泛的组织资源，对我们的孢子有价值 以及我们计划组织的更广泛的网络。上峰会是 由MSKCC委员会和著名的科学顾问委员会。

We here propose a Specialized Program of Research Excellence in Breast Cancer to meet the needs of the oncologic community for an integrated clinical and laboratory effort dedicated to reducing the incidence of and mortality from breast cancer. The SPORE will be composed of one Director one Scientific Coordinator, a Steering Committee, five main research projects, two core resources (Administrative and Pathology), a Developmental Research Program, and a Career Development Program. The projects will include studies of erbB-2, erbB-3, and erbB-4, heregulin, EGFR, ras and farnesyl protein transferase inhibitors, TC- 21, TGF-beta, representational difference analysis, susceptibility genes (BRCA1), cyclins, and p53. These laboratory investigations will translate into a better understanding of etiology, diagnosis, staging, prognosis, therapeutic response, and quality-of-life. The Steering Committee will consist of the Director (Dr. Norton), the Scientific Coordinator (Dr. N. Rosen), the Head of the Breast Pathology Core Resource (Dr. P. P. Rosen), the leaders of the five main projects (Drs. Aaronson, Massague, Mendelsohn, N. Rosen, Wigler), Dr. Lucio Luzzatto (Human Genetics), Dr. Begg (Biostatistics), Dr. Lloyd Old (Immunology), Dr. Borgen (Surgery), Dr. Beryl McCormick (Radiation Therapy), and Ms. Amy Langer (Executive Director, National Alliance of Breast Cancer Organizations). To expedite an improved SPORE network, we advocate and will organize frequent meetings of the Directors of the funded SPOREs. We would also propose to coordinate our activities with those of representatives of the various NCI- sponsored tissue resource banks/registries other than the SPOREs, and with the chairs of the Cooperative Group Breast Cancer Committees. We have designed an extensive tissue resource to be of value to our SPORE and to the wider network that -we plan to organize. Oversight will be by MSKCC committees and by an eminent Board of Scientific Advisors.